ipilimumab,nivolumab
bms
['nivo', 'ipilimumab', 'check,mate,227', 'nivolumab', 'lung', 'yervoy', 'opdivo', '$bmy']
landmark five-year data from phase 3 #checkmate227 trial demonstrate long-term, durable survival outcomes with #opdivo (#nivolumab) plus #yervoy (#ipilimumab) in first-line treatment of patients with metastatic #nonsmallcelllungcancer #asco22 $bmy 
Follow top-line development in the oncology commercial domain. Gain entry to KOL discussions, including both medical professionals and business leaders.